Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety rollover study of oral brigimadlin (BI 907828) in patients with solid tumours
2024-514177-21-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, open-label, single-arm trial of brigimadlin in Nonhematologic neoplasms, sponsored by Boehringer Ingelheim. Planned start Oct 2024; status: authorised.
02
Drugs
brigimadlin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-514177-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514177-21-00.